- Home
- MGRX vs BCAB Comparison
MGRX vs BCAB Comparison
Compare MGRX & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | BCAB |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.4M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MGRX | BCAB |
|---|---|---|
| Price | $0.47 | $4.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 591.7K | 51.5K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $456,021.00 | $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.12 |
| 52 Week High | $2.75 | $6.52 |
Technical Indicators
Market Signals| Indicator | MGRX | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 65.16 | 59.93 |
| Support Level | $0.34 | $3.92 |
| Resistance Level | $0.49 | $4.22 |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 100.00 | 88.54 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.